United States Influenza Vaccines Market Size, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2031
The influenza vaccines market in the United States was valued at US$ 3,962 billion in 2022 and is expected to reach US$ 8,347 billion by 2031, registering a CAGR of 8.6% during the forecast period.
Rapid market expansion is primarily due to increased research and development, the introduction of quadrivalent influenza vaccines, the aging population, and vaccine awareness. In addition, expanded recommendations from government and advisory bodies to get influenza vaccines are driving market growth in the United States.
Influenza is the second leading cause of death from vaccine-preventable disease in the United States after COVID-19. Rates of seasonal influenza infection are highest in children, but the risks for complications, hospitalizations, and deaths are higher in adults 65 years of age and older, children younger than 5 years, pregnant women, and people of any age with conditions that place them at increased risk for influenza complications.
The report on the influenza vaccines market in the United States is a comprehensive study and presentation of drivers, restraints, opportunities, demand, market size, forecasts, and trends in the influenza vaccines market in the United States during 2018-2031. In addition, the report is a collective presentation of primary and secondary research findings.
Key Market Developments
Rapid market expansion is primarily due to increased research and development, the introduction of quadrivalent influenza vaccines, the aging population, and vaccine awareness. In addition, expanded recommendations from government and advisory bodies to get influenza vaccines are driving market growth in the United States.
Influenza is the second leading cause of death from vaccine-preventable disease in the United States after COVID-19. Rates of seasonal influenza infection are highest in children, but the risks for complications, hospitalizations, and deaths are higher in adults 65 years of age and older, children younger than 5 years, pregnant women, and people of any age with conditions that place them at increased risk for influenza complications.
The report on the influenza vaccines market in the United States is a comprehensive study and presentation of drivers, restraints, opportunities, demand, market size, forecasts, and trends in the influenza vaccines market in the United States during 2018-2031. In addition, the report is a collective presentation of primary and secondary research findings.
Key Market Developments
- The United States continues to be the world’s largest influenza vaccines market
- Demand for influenza vaccines is expected to increase over the forecast period due to the pandemic COVID -19
- Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, A Seasonal Influenza Vaccine Candidate
- Novavax announces initiation of Phase 2 study for COVID-19 influenza combination vaccine and stand-alone influenza vaccine candidate
- GSK and CureVac advance mRNA COVID-19 and influenza vaccine candidates
- Seqirus receives a government contract to develop 2 influenza vaccines
- Chapter 1 contains a brief description of the market under study
- Chapter 2 describes the research methodology of the study
- Chapter 3 identifies key trends and prospects for the U.S. influenza vaccine market and draws key conclusions
- Chapter 4 discusses the market scenario for influenza vaccines in the United States in terms of historical market values and projections through 2031
- Chapter 5 analysis of adults and children in the United States vaccinated with influenza vaccines and projection through 2031
- Chapter 6 highlights key market dynamics in the U.S. influenza vaccine market, including factors driving the market, prevailing barriers, potential opportunities, and future trends. This section also includes an analysis of the impact of the driving and restraining factors
- Chapter 7 offers comprehensive insights into the latest pricing trends and analysis of the U.S. influenza vaccine market
- Chapter 8 includes a comprehensive analysis of influenza vaccine production, supply, and distribution in the United States (by company)
- Chapter 9 provides a complete overview of influenza vaccine distribution and demand in the United States
- Chapter 10 investigates the effectiveness of influenza vaccines in the United States
- Chapter 11 thorough evaluation of rapid diagnostic tests for influenza management
- Chapter 12 carefully evaluates the distribution channel and technique of influenza vaccination in the United States
- Chapter 13 characteristics of reimbursement structures in the influenza vaccine market in the united states
- Chapter 14 detailed insights into the legal framework of the U.S. influenza vaccine market
- Chapter 15 tracks competitive developments, approaches, recent industry developments, and mergers and acquisitions, collaboration, distribution, exclusivity, and licensing agreements.
- Chapter 16 an informative study was conducted on promising influenza vaccines in clinical development.
- Chapter 17 analyses recent clinical trials of the influenza vaccine
- Chapter 18 and 19 provides the industry landscape and detailed profiles of key and promising companies operating in the influenza vaccine market in the United States. The companies have been profiled based on their key facts, business description, products and services, current vaccine portfolio, promising vaccines in clinical development, platform technology, and key developments.
- Chapter 20, i.e. the appendix contains a brief overview of the company, a glossary, contact information, and the disclaimer section.
- Sanofi Pasteur
- GlaxoSmithKline (GSK)
- Seqirus (CSL Limited)
- AstraZeneca
- Novavax
- Medicago
- Moderna Inc
- Pneumagen
- Daiichi–Sankyo
- Altimmune
- FluGen
- Imutex
- EpiVax, Inc
- Versatope Therapeutics, Inc
- BiondVax Pharmaceuticals Ltd.
- What is the current size of the U.S. influenza vaccine market?
- What will be the CAGR of the influenza vaccine market in the United States?
- How many people will be vaccinated with flu vaccines in the U.S. between 2018 and 2031?
- What percentage of people in the United States get vaccinated against influenza?
- What are the main flu vaccines available in the United States?
- What are the key drivers of the influenza vaccine market in the United States?
- What are the major barriers to the influenza vaccine market in the United States?
- What is the reimbursement pattern in the influenza vaccine market in the United States?
- What is the regulatory framework for the influenza vaccine market in the United States?
- What are the key deals and agreements in the United States influenza vaccine market?
- What are the upcoming flu vaccines that will significantly impact the market in the future?
- Who are the main market participants? What is happening with them, what revenues do they generate from vaccines, and what are the current developments and scenarios?
- Who are the new players? What are their events, clinical developments, platform technologies, phases, and current developments?
- How is the market likely to develop in the future?
1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. UNITED STATES INFLUENZA VACCINES MARKET SIZE, INSIGHTS, ANALYSIS, AND FORECASTS (2018 - 2031)
5. UNITED STATES NUMBER OF PERSONS VACCINATED WITH INFLUENZA VACCINES (2018 - 2031)
5.1 Number of Children Vaccinated with Influenza Vaccines
5.2 Number of Adults Vaccinated with Influenza Vaccines
6. KEY MARKET GROWTH DRIVERS AND CHALLENGES OF THE UNITED STATES INFLUENZA VACCINES MARKET
6.1 Market Drivers
6.2 Market Challenges
7. UNITED STATES INFLUENZA VACCINES PRICING ANALYSIS, TRENDS AND INSIGHTS
8. UNITED STATES INFLUENZA VACCINES PRODUCTION, SUPPLY, AND ALLOCATION (BY COMPANIES),2014 - 2022
9. UNITED STATES INFLUENZA VACCINES DISTRIBUTION AND DEMAND ANALYSIS 2010 - 2022
10. EFFECTIVENESS OF INFLUENZA VACCINES IN THE UNITED STATES, 2004 – 2022
11. RAPID DIAGNOSTIC TESTING FOR THE MANAGEMENT OF INFLUENZA
12. DISTRIBUTION CHANNEL AND TECHNIQUE DETAILED INSIGHTS OF INFLUENZA VACCINATION IN THE UNITED STATES
13. REIMBURSEMENT ENVIRONMENT OF THE UNITED STATES INFLUENZA VACCINES MARKET
14. REGULATORY FRAMEWORK OF THE UNITED STATES INFLUENZA VACCINES MARKET
15. MAJOR DEALS AND AGREEMENT ACTIVITIES IN THE INFLUENZA VACCINES MARKET
15.1 Merger and Acquisitions
15.2 Collaboration Deals
15.3 Licensing Agreement
15.4 Exclusive Agreement
15.5 Distribution Agreement
16. PROMISING INFLUENZA VACCINES IN THE CLINICAL DEVELOPMENT
17. INFLUENZA VACCINES CLINICAL TRIAL INSIGHTS BY PHASE, COMPANY AND COUNTRY
17.1 Year 2022
17.2 Year 2021
17.3 Year 2020
18. COMPANY PROFILES
18.1 Sanofi Pasteur
18.1.1 Business Overview
18.1.2 Influenza Vaccines Portfolio
18.1.3 Influenza Vaccines Sales Value Analysis
18.1.4 Promising Influenza Vaccines in the Clinical Development
18.1.5 Recent Development
18.2 GlaxoSmithKline (GSK)
18.2.1 Business Overview
18.2.2 Influenza Vaccines Portfolio
18.2.3 Influenza Vaccines Sales Value Analysis
18.2.4 Recent Development
18.3 Seqirus
18.3.1 Business Overview
18.3.2 Influenza Vaccines Portfolios
18.3.3 Influenza Vaccines Sales Value Analysis
18.3.4 Promising Influenza Vaccines in the Clinical Development
18.3.5 Recent Development
18.4 AstraZeneca
18.4.1 Business Overview
18.4.2 Influenza Vaccines Portfolio
18.4.3 Influenza Vaccines Sales Value Analysis
18.4.4 Recent Development
19. EMERGING COMPANY PROFILES
19.1 Novavax
19.1.1 Business Overview
19.1.2 Promising Influenza Vaccines in the Clinical Development
19.1.3 Recent Development
19.2 BiondVax Pharmaceuticals Ltd.
19.2.1 Business Overview
19.2.2 Promising Influenza Vaccines in the Clinical Development
19.2.3 Recent Development
19.3 Medicago
19.3.1 Business Overview
19.3.2 Promising Influenza Vaccines in the Clinical Development
19.3.3 Recent Development
19.4 Moderna Inc
19.4.1 Business Overview
19.4.2 Promising Influenza Vaccines in the Clinical Development
19.4.3 Recent Development
19.5 Pneumagen
19.5.1 Business Overview
19.5.2 Promising Influenza Vaccines in the Clinical Development
19.5.3 Recent Development
19.6 Altimmune
19.6.1 Business Overview
19.6.2 Promising Influenza Vaccines in the Clinical Development
19.6.3 Recent Development
19.7 Daiichi Sankyo
19.7.1 Business Overview
19.7.2 Promising Influenza Vaccines in the Clinical Development
19.7.3 Recent Development
19.8 FluGen
19.8.1 Business Overview
19.8.2 Promising Influenza Vaccines in the Clinical Development
19.8.3 Recent Development
19.9 Imutex
19.9.1 Business Overview
19.9.2 Promising Vaccines in the Clinical Development
19.9.3 Recent Development
19.10 EpiVax
19.10.1 Business Overview
19.10.2 Promising Influenza Vaccines in the Clinical Development
19.10.3 Recent Development
19.11 Versatope Therapeutics, Inc.
19.11.1 Business Overview
19.11.2 Promising Influenza Vaccines in the Clinical Development
19.11.3 Recent Development
20. APPENDIX
20.1 About DPI Research
20.2 Glossary of Terms
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. UNITED STATES INFLUENZA VACCINES MARKET SIZE, INSIGHTS, ANALYSIS, AND FORECASTS (2018 - 2031)
5. UNITED STATES NUMBER OF PERSONS VACCINATED WITH INFLUENZA VACCINES (2018 - 2031)
5.1 Number of Children Vaccinated with Influenza Vaccines
5.2 Number of Adults Vaccinated with Influenza Vaccines
6. KEY MARKET GROWTH DRIVERS AND CHALLENGES OF THE UNITED STATES INFLUENZA VACCINES MARKET
6.1 Market Drivers
6.2 Market Challenges
7. UNITED STATES INFLUENZA VACCINES PRICING ANALYSIS, TRENDS AND INSIGHTS
8. UNITED STATES INFLUENZA VACCINES PRODUCTION, SUPPLY, AND ALLOCATION (BY COMPANIES),2014 - 2022
9. UNITED STATES INFLUENZA VACCINES DISTRIBUTION AND DEMAND ANALYSIS 2010 - 2022
10. EFFECTIVENESS OF INFLUENZA VACCINES IN THE UNITED STATES, 2004 – 2022
11. RAPID DIAGNOSTIC TESTING FOR THE MANAGEMENT OF INFLUENZA
12. DISTRIBUTION CHANNEL AND TECHNIQUE DETAILED INSIGHTS OF INFLUENZA VACCINATION IN THE UNITED STATES
13. REIMBURSEMENT ENVIRONMENT OF THE UNITED STATES INFLUENZA VACCINES MARKET
14. REGULATORY FRAMEWORK OF THE UNITED STATES INFLUENZA VACCINES MARKET
15. MAJOR DEALS AND AGREEMENT ACTIVITIES IN THE INFLUENZA VACCINES MARKET
15.1 Merger and Acquisitions
15.2 Collaboration Deals
15.3 Licensing Agreement
15.4 Exclusive Agreement
15.5 Distribution Agreement
16. PROMISING INFLUENZA VACCINES IN THE CLINICAL DEVELOPMENT
17. INFLUENZA VACCINES CLINICAL TRIAL INSIGHTS BY PHASE, COMPANY AND COUNTRY
17.1 Year 2022
17.2 Year 2021
17.3 Year 2020
18. COMPANY PROFILES
18.1 Sanofi Pasteur
18.1.1 Business Overview
18.1.2 Influenza Vaccines Portfolio
18.1.3 Influenza Vaccines Sales Value Analysis
18.1.4 Promising Influenza Vaccines in the Clinical Development
18.1.5 Recent Development
18.2 GlaxoSmithKline (GSK)
18.2.1 Business Overview
18.2.2 Influenza Vaccines Portfolio
18.2.3 Influenza Vaccines Sales Value Analysis
18.2.4 Recent Development
18.3 Seqirus
18.3.1 Business Overview
18.3.2 Influenza Vaccines Portfolios
18.3.3 Influenza Vaccines Sales Value Analysis
18.3.4 Promising Influenza Vaccines in the Clinical Development
18.3.5 Recent Development
18.4 AstraZeneca
18.4.1 Business Overview
18.4.2 Influenza Vaccines Portfolio
18.4.3 Influenza Vaccines Sales Value Analysis
18.4.4 Recent Development
19. EMERGING COMPANY PROFILES
19.1 Novavax
19.1.1 Business Overview
19.1.2 Promising Influenza Vaccines in the Clinical Development
19.1.3 Recent Development
19.2 BiondVax Pharmaceuticals Ltd.
19.2.1 Business Overview
19.2.2 Promising Influenza Vaccines in the Clinical Development
19.2.3 Recent Development
19.3 Medicago
19.3.1 Business Overview
19.3.2 Promising Influenza Vaccines in the Clinical Development
19.3.3 Recent Development
19.4 Moderna Inc
19.4.1 Business Overview
19.4.2 Promising Influenza Vaccines in the Clinical Development
19.4.3 Recent Development
19.5 Pneumagen
19.5.1 Business Overview
19.5.2 Promising Influenza Vaccines in the Clinical Development
19.5.3 Recent Development
19.6 Altimmune
19.6.1 Business Overview
19.6.2 Promising Influenza Vaccines in the Clinical Development
19.6.3 Recent Development
19.7 Daiichi Sankyo
19.7.1 Business Overview
19.7.2 Promising Influenza Vaccines in the Clinical Development
19.7.3 Recent Development
19.8 FluGen
19.8.1 Business Overview
19.8.2 Promising Influenza Vaccines in the Clinical Development
19.8.3 Recent Development
19.9 Imutex
19.9.1 Business Overview
19.9.2 Promising Vaccines in the Clinical Development
19.9.3 Recent Development
19.10 EpiVax
19.10.1 Business Overview
19.10.2 Promising Influenza Vaccines in the Clinical Development
19.10.3 Recent Development
19.11 Versatope Therapeutics, Inc.
19.11.1 Business Overview
19.11.2 Promising Influenza Vaccines in the Clinical Development
19.11.3 Recent Development
20. APPENDIX
20.1 About DPI Research
20.2 Glossary of Terms
LIST OF TABLES:
Table 7 1: United States Pediatric Influenza Vaccines Price, 2022 – 2023
Table 7 2: United States Adult Influenza Vaccines Price, 2022 – 2023
Table 8 1: United States Influenza Vaccines Production, Supply, and Allocation
Table 9 1: Total Percentage of Influenza Vaccines Released by Week, 2021 – 2022
Table 9 2: Total Percentage of Influenza Vaccines Released by Week, 2020 – 2021
Table 9 3: Total Percentage of Influenza Vaccines Released by Week, 2019 – 2020
Table 9 4: Total Percentage of Influenza Vaccines Released by Week,2018 – 2019
Table 9 5: Total Percentage of Influenza Vaccines Released by Week,2017 – 2018
Table 9 6: Total Percentage of Influenza Vaccines Released by Week,2016 – 2017
Table 9 7: Total Percentage of Influenza Vaccines Released by Week,2015 – 2016
Table 9 8: Total Percentage of Influenza Vaccines Released by Week,2014 – 2015
Table 10 1: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 – 2021
Table 11 1: Influenza Virus Testing Methods
Table 12 1: Distribution of Influenza Vaccination
Table 14 1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 15 1: Merger & Acquisitions in the Influenza Vaccines Market
Table 15 2: Collaboration Deal in the Influenza Vaccines Market
Table 15 3: Licensing Agreement in the Influenza Vaccines Market
Table 15 4: Exclusive Agreement in the Influenza Vaccines Market
Table 15 5: Distribution Agreement in the Influenza Vaccines Market
Table 16 1: BiondVax Pharmaceuticals Ltd. – Clinical Trials
Table 18 1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development
Table 18 2: Seqirus Promising Influenza Vaccines in the Clinical Development
Table 19 1: Novavax Promising Influenza Vaccines in the Clinical Development
Table 19 2: Biondvax Promising Influenza Vaccines in the Clinical Development
Table 19 3: Medicago Promising Influenza Vaccines in the Clinical Development
Table 19 4: Moderna Promising Influenza Vaccines in the Clinical Development
Table 19 5: Pneumagen Promising Influenza Vaccines in the Clinical Development
Table 19 6: Altimmune Promising Influenza Vaccines in the Clinical Development
Table 19 7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development
Table 19 8: FluGen Promising Influenza Vaccines in the Clinical Development
Table 19 9: Imutex Promising Influenza Vaccines in the Clinical Development
Table 19 10: EpiVax Promising Influenza Vaccines in the Clinical Development
Table 19 11: Versatope Therapeutics, Inc. Promising Influenza Vaccines in the Clinical Development
Table 7 1: United States Pediatric Influenza Vaccines Price, 2022 – 2023
Table 7 2: United States Adult Influenza Vaccines Price, 2022 – 2023
Table 8 1: United States Influenza Vaccines Production, Supply, and Allocation
Table 9 1: Total Percentage of Influenza Vaccines Released by Week, 2021 – 2022
Table 9 2: Total Percentage of Influenza Vaccines Released by Week, 2020 – 2021
Table 9 3: Total Percentage of Influenza Vaccines Released by Week, 2019 – 2020
Table 9 4: Total Percentage of Influenza Vaccines Released by Week,2018 – 2019
Table 9 5: Total Percentage of Influenza Vaccines Released by Week,2017 – 2018
Table 9 6: Total Percentage of Influenza Vaccines Released by Week,2016 – 2017
Table 9 7: Total Percentage of Influenza Vaccines Released by Week,2015 – 2016
Table 9 8: Total Percentage of Influenza Vaccines Released by Week,2014 – 2015
Table 10 1: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2004 – 2021
Table 11 1: Influenza Virus Testing Methods
Table 12 1: Distribution of Influenza Vaccination
Table 14 1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 15 1: Merger & Acquisitions in the Influenza Vaccines Market
Table 15 2: Collaboration Deal in the Influenza Vaccines Market
Table 15 3: Licensing Agreement in the Influenza Vaccines Market
Table 15 4: Exclusive Agreement in the Influenza Vaccines Market
Table 15 5: Distribution Agreement in the Influenza Vaccines Market
Table 16 1: BiondVax Pharmaceuticals Ltd. – Clinical Trials
Table 18 1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development
Table 18 2: Seqirus Promising Influenza Vaccines in the Clinical Development
Table 19 1: Novavax Promising Influenza Vaccines in the Clinical Development
Table 19 2: Biondvax Promising Influenza Vaccines in the Clinical Development
Table 19 3: Medicago Promising Influenza Vaccines in the Clinical Development
Table 19 4: Moderna Promising Influenza Vaccines in the Clinical Development
Table 19 5: Pneumagen Promising Influenza Vaccines in the Clinical Development
Table 19 6: Altimmune Promising Influenza Vaccines in the Clinical Development
Table 19 7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development
Table 19 8: FluGen Promising Influenza Vaccines in the Clinical Development
Table 19 9: Imutex Promising Influenza Vaccines in the Clinical Development
Table 19 10: EpiVax Promising Influenza Vaccines in the Clinical Development
Table 19 11: Versatope Therapeutics, Inc. Promising Influenza Vaccines in the Clinical Development
LIST OF FIGURES:
Figure 2 1: United States Influenza Vaccines Market Size and Analysis (Million US$),2018 – 2022
Figure 2 2: United States Influenza Vaccines Market Size and Forecast (Million US$),2023 – 2031
Figure 3 1: United States Total Number of Individuals Vaccinated with Influenza Vaccines (Thousand), 2018 – 2022
Figure 3 2: United States Total Number of Individuals Vaccinated with Influenza Vaccines Forecast (Thousand), 2023 – 2031
Figure 3 3: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2018 – 2022
Figure 3 4: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2023 – 2031
Figure 3 5: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2018 – 2022
Figure 3 6: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2023 – 2031
Figure 7 1: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 – 2022
Figure 10 1: United States Place of Influenza Vaccination for Children and Adults (Percent),2021 - 2022
Figure 16 1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2018 – 2022
Figure 16 2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2023 – 2031
Figure 16 3: GSK Influenza Vaccines Net Sales Value (Million US$),2018 – 2022
Figure 16 4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2023 – 2031
Figure 16 5: Seqirus Influenza Vaccines Net Sales Value (Million US$),2018 – 2022
Figure 16 6: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US$),2023 – 2031
Figure 16 7: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2018 – 2022
Figure 16 8: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2023 – 2031
Figure 2 1: United States Influenza Vaccines Market Size and Analysis (Million US$),2018 – 2022
Figure 2 2: United States Influenza Vaccines Market Size and Forecast (Million US$),2023 – 2031
Figure 3 1: United States Total Number of Individuals Vaccinated with Influenza Vaccines (Thousand), 2018 – 2022
Figure 3 2: United States Total Number of Individuals Vaccinated with Influenza Vaccines Forecast (Thousand), 2023 – 2031
Figure 3 3: United States Number of Children Vaccinated with Influenza Vaccines (Thousand),2018 – 2022
Figure 3 4: United States Number of Children Vaccinated with Influenza Vaccines Forecast (Thousand),2023 – 2031
Figure 3 5: United States Number of Adults Vaccinated with Influenza Vaccines (Thousand),2018 – 2022
Figure 3 6: United States Number of Adults Vaccinated with Influenza Vaccines Forecast (Thousand),2023 – 2031
Figure 7 1: United States Influenza Vaccine Doses Distributed, By Season (Million),2010 – 2022
Figure 10 1: United States Place of Influenza Vaccination for Children and Adults (Percent),2021 - 2022
Figure 16 1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$),2018 – 2022
Figure 16 2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$),2023 – 2031
Figure 16 3: GSK Influenza Vaccines Net Sales Value (Million US$),2018 – 2022
Figure 16 4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$),2023 – 2031
Figure 16 5: Seqirus Influenza Vaccines Net Sales Value (Million US$),2018 – 2022
Figure 16 6: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US$),2023 – 2031
Figure 16 7: AstraZeneca Influenza Vaccines Net Sales Value (Million US$),2018 – 2022
Figure 16 8: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$),2023 – 2031
